New biologic agents for the treatment of cutaneous T-cell lymphoma.
Cutaneous T-cell lymphoma (CTCL) is typically a skin-infiltrating malignancy of clonally derived CD4+ T lymphocytes. Because the host antitumor response appears to play an important role in disease control, systemic therapeutic agents are used in such a manner as to preserve the integrity of the host antitumor response while selectively targeting the malignant cells. The new biologic response-modifying treatment options currently used to treat CTCL are reviewed.
Vittorio
Carmela C
CC
University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA.
Junkins-Hopkins
Jacqueline M
JM
McGinnis
Karen S
KS
Shapiro
Michael
M
Wysocka
Maria
M
Zaki
Mohamed H
MH
French
Lars E
LE
Rook
Alain H
AH
D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology; D017893:Photopheresis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology
D007155:Immunologic Factors